Onychauxis, also known as nail hypertrophy, is a common nail disorder characterized by excessive thickening of the nail plate without significant deformity or curvature. The condition most frequently affects the toenails, particularly the hallux (big toe), but can involve fingernails as well. Unlike onychogryphosis, which features ram’s-horn-like distortion, onychauxis presents as uniform or irregular hypertrophy that can reach several millimeters in thickness. This can cause pain, difficulty wearing shoes, secondary infections, and significant cosmetic concern. The condition is especially prevalent in the elderly, diabetics, and those with peripheral vascular disease, with incidence increasing with age. Effective treatment requires accurate diagnosis, identification of underlying causes, and a tailored multimodal approach combining mechanical, pharmacological, and occasionally surgical interventions.

The primary goal of treatment of onychauxis is to reduce nail thickness, alleviate symptoms, restore function, and prevent complications such as onychomycosis, paronychia, or subungual ulceration. Success depends heavily on addressing any contributing systemic or local factors.

Etiology and Contributing Factors

Onychauxis rarely occurs in isolation. Common causes include repeated microtrauma (ill-fitting footwear, occupational pressure), dermatological conditions (psoriasis, lichen planus, Darier’s disease), fungal infections (dermatophytes or Candida), systemic diseases (diabetes mellitus, peripheral arterial disease, hypothyroidism), and congenital disorders (pachyonychia congenita). In many cases, especially in older adults, it represents a cumulative response to decades of minor trauma superimposed on age-related reduction in nail growth rate and peripheral circulation.

Diagnosis

Diagnosis is primarily clinical. The thickened nail is typically opaque, yellow-brown, and difficult to trim with standard clippers. Dermoscopy can help differentiate onychauxis from onychomycosis or subungual hematoma. When fungal infection is suspected, KOH preparation, fungal culture, or PAS staining of nail clippings is essential, as up to 30–50% of dystrophic nails in the elderly are mycotic. Imaging (X-ray or ultrasound) is rarely needed unless subungual exostosis or tumor is suspected.

Conservative and Mechanical Management

The cornerstone of treatment for most patients is regular professional debridement performed by a podiatrist. Using specialized nail nippers and electric or manual burrs, the clinician reduces nail thickness to near-normal levels every 8–12 weeks. This provides immediate symptomatic relief and prevents secondary complications.

Between visits, patients are prescribed 40% urea cream (or compounded 50% urea paste) applied under occlusion overnight to soften the nail plate. The softened hyperkeratotic material is then gently filed with a disposable emery board. Urea works by disrupting hydrogen bonds in keratin, dramatically improving nail pliability within days. This regimen, when followed diligently, can reduce nail thickness by 50–70% over several months.

Topical keratolytics containing salicylic acid (6–17%) or lactic acid (12%) in collodion or cream bases are alternatives for patients intolerant to urea. Bifonazole 1%/urea 40% combination (available in some countries) offers the advantage of simultaneous antifungal action.

Proper footwear is critical. Patients should wear shoes with a wide, deep toe box and avoid high heels. Custom orthotics may be required to redistribute pressure in cases of biomechanical abnormality.

Pharmacological Treatment

When onychomycosis is confirmed, systemic or topical antifungals are indicated. Oral terbinafine (250 mg daily for 12–16 weeks for toenails) remains the gold standard, achieving mycological cure rates of approximately 76% and complete cure rates around 38–50% in hypertrophic nails. Itraconazole pulse therapy (400 mg daily for 1 week per month, 3–4 pulses) is an alternative, particularly in Candida or non-dermatophyte infections.

Newer topical agents—efinaconazole 10%, tavaborole 5%, and amorolfine 5% lacquer—penetrate thickened nails better than older formulations and are useful in mild-to-moderate cases or when systemic therapy is contraindicated. However, cure rates are lower (15–55%) in severely hypertrophic nails due to impaired drug delivery.

For inflammatory dermatoses (psoriasis, eczema), high-potency topical corticosteroids under occlusion or intralesional triamcinolone can reduce associated subungual hyperkeratosis. Systemic therapies (methotrexate, acitretin, biologics) may be required in severe cases.

Advanced and Surgical Options

When conservative measures fail and the nail remains painfully thick or repeatedly infected, surgical intervention is considered.

Chemical matrixectomy using 88% phenol or 10% sodium hydroxide following partial or total nail avulsion is highly effective for permanent reduction of nail thickness and has success rates exceeding 95% in preventing regrowth. The procedure is performed under local anesthesia and is particularly suitable for elderly patients or those with vascular compromise.

Laser therapy (1064-nm Nd:YAG, fractional CO2) has shown promise in reducing nail thickness and treating associated onychomycosis, with studies reporting 60–80% improvement in nail appearance at 6–12 months. However, cost and variable insurance coverage limit widespread adoption.

Photodynamic therapy using aminolevulinic acid and red light has demonstrated efficacy in small series, particularly for antifungal-resistant cases.

Special Populations

In diabetic patients, meticulous foot care and early podiatric referral are essential to prevent ulceration. Prophylactic debridement every 8–10 weeks is often recommended.

In pachyonychia congenita, genetic counseling and aggressive mechanical reduction combined with oral retinoids may provide partial relief, though no cure exists.

Prevention and Patient Education

Prevention centers on trauma minimization and early treatment of predisposing conditions. Patients should:

• Trim nails straight across and file thick edges
• Keep feet dry and use antifungal powder prophylactically
• Wear properly fitted shoes and moisture-wicking socks
• Moisturize the nail plate and surrounding skin daily
• Seek early treatment for any nail changes

Onychauxis, while rarely life-threatening, significantly impacts quality of life through pain, mobility limitation, and psychological distress. Successful management requires a systematic approach: accurate diagnosis, treatment of underlying causes, regular professional debridement, topical keratolytics, and, when necessary, systemic or surgical intervention. With consistent care, most patients achieve substantial improvement in nail appearance and comfort. The combination of 40% urea cream and periodic podiatric reduction has transformed what was once a frustrating, intractable condition into one that is highly manageable for the vast majority of sufferers.

Early intervention and patient compliance are the most important predictors of outcome. In an aging population with increasing rates of diabetes and peripheral vascular disease, podiatrists and dermatologists will continue to play a crucial role in preventing the morbidity associated with this common but often overlooked nail disorder.